You are here

RNAi

Novartis’s big wager on RNAi approaches the finish line

Novartis’s big wager on RNAi approaches the finish line

EP Vantage

Flag link:

Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?

Can Either of These Little-Known Biotechs Find New Life Fighting Coronavirus?

Motley Fool

Vir Biotechnology

Flag link:

Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug

Takeda drops $300M cash to kick off $1B RNAi alliance with Arrowhead, shooting for first-in-class rare disease drug

Endpoints

Arrowhead Pharmaceuticals

Flag link:

Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants

Alnylam phase 3 links lumasiran to 'clinically significant' improvement in infants

Fierce Biotech

clinical trials

Flag link:

Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug

Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug

Xconomy

Arrowhead Pharmaceuticals

clinical trials

Flag link:

New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race

New data from J&J, Arrowhead mark latest step in RNAi's hepatitis B race

BioPharma Dive

Arrowhead Pharmaceuticals

clinical trials

Flag link:

J&J's RNAi suppresses hepatitis B for 48 weeks after last dose

J&J's RNAi suppresses hepatitis B for 48 weeks after last dose

Fierce Biotech

Flag link:

EASL 2020 – Assembly finds a partner as hepatitis B inches forward

EASL 2020 – Assembly finds a partner as hepatitis B inches forward

EP Vantage

Assembly Biosciences

Vir Biotechnology

Flag link:

Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA

Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA

Endpoints

New England Journal of Medicine

Flag link:

Bayer helps Harvard spinout Vesigen to $28.5M series A

Bayer helps Harvard spinout Vesigen to $28.5M series A

Fierce Biotech

Vesigen Therapeutics

Flag link:

Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show

Alnylam's RNAi therapy Givlaari shows lasting effect one year into treatment, new data show

Fierce Pharma

acute hepatic porphyria

Flag link:

Dicerna nabs speedy review voucher for leading RNAi drug

Dicerna nabs speedy review voucher for leading RNAi drug

Fierce Biotech

priority review

Flag link:

Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data

Alnylam sets up 3rd potential RNAi approval with a showcase of positive lumasiran data

Endpoints

clinical trials

Flag link:

Alnylam nabs speedy review, setting up 3rd possible approval in 3 years

Alnylam nabs speedy review, setting up 3rd possible approval in 3 years

Endpoints

Flag link:

Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral

Alnylam, Vir plan year-end trial of new RNAi COVID-19 antiviral

Fierce Biotech

Vir Biotechnology

clinical trials

Flag link:

Alnylam's vutrisiran gets fast-track treatment at the FDA

Alnylam's vutrisiran gets fast-track treatment at the FDA

Fierce Biotech

Flag link:

Blackstone backs Alnylam with up to $2B investment

Blackstone backs Alnylam with up to $2B investment

BioPharma Dive

Flag link:

Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis

Arrowhead Pharmaceuticals files for regulatory clearance to begin phase 1/2a study of ARO-ENaC for treatment of cystic fibrosis

Pharmaceutical Business Review

Arrowhead Pharmaceuticals

clinical trials

cystic fibrosis

Flag link:

After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration

After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration

Endpoints

John Maraganore

Douglas Fambrough

Flag link:

Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19

Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19

Pharmaceutical Business Review

Vir Biotechnology

drug development

Flag link:

Pages